Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medlive Technology CoFRA:1JZ +2.93%90 EBITDA Margin % is 62.27% as of Dec. 2025, which is 27% above its 10-year median of 48.86. GuruFocus rates FRA:1JZ with a GF Score™ of 90/100 and a GF Value™ of €1.61. The stock has 5 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Medlive Technology Co ranks better than 98.34% on this metric.
Medlive Technology Co (FRA:1JZ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medlive Technology Co EBITDA Margin % Related Terms
Medlive Technology Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medlive Technology Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1JZ vs VEEV, BTSG, HQY: EBITDA Margin % Comparison
For the Health Information Services subindustry, Medlive Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medlive Technology Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medlive Technology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medlive Technology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medlive Technology Co (FRA:1JZ) has a EBITDA Margin % of 62.27% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medlive Technology Co and its competitors. This is 27% above median its historical median of 48.86. Over the past decade, Medlive Technology Co's EBITDA Margin % has ranged from 24.94 to 63.90. According to the industry distribution chart, Medlive Technology Co ranks #11 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 1.7%.
Is Medlive Technology Co's EBITDA Margin % too high?
Medlive Technology Co's current EBITDA Margin % of 62.27% is 27% above median its 10-year median of 48.86. Over the past 10 years, this metric has ranged from a low of 24.94 to a high of 63.90. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Medlive Technology Co's value of 62.27% is 509.9% above this industry median. Based on the distribution chart, Medlive Technology Co ranks #11 out of 662 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medlive Technology Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Medlive Technology Co ranks #11 out of 662 companies for EBITDA Margin %. This places Medlive Technology Co in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Medlive Technology Co's value of 62.27% is 509.9% above this benchmark. Historically, Medlive Technology Co's own EBITDA Margin % has ranged from 24.94 to 63.90 over the past decade. While the company's 10-year median is 48.86 vs. the industry median of 10.21, Medlive Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medlive Technology Co's current EBITDA Margin % of 62.27% is 509.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medlive Technology Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medlive Technology Co's current EBITDA Margin % is 62.27%, which is 27% above median its own 10-year median of 48.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Medlive Technology Co (FRA:1JZ) has a current EBITDA Margin % of 62.27%. The stock's GF Value™ is €1.61, compared to a current price of €0.84 — trading 47.6% below its estimated fair value. The current EBITDA Margin % is 62.27%, which is 27% above median its 10-year median of 48.86 and 509.9% above the Healthcare Providers & Services industry median of 10.21. Medlive Technology Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medlive Technology Co (FRA:1JZ), the current EBITDA Margin % is 62.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (FRA:1JZ) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of €0.84 is trading 47.6% below its estimated GF Value™ of €1.61.
Key valuation signals for FRA:1JZ:
EBITDA Margin %: 62.27% (27% above median its 10-year median of 48.86)
GF Value™: €1.61 vs. price of €0.84 (47.6% below fair value)
Industry Position: 509.9% above the Healthcare Providers & Services median (#11 of 662)
No single metric tells the full story. See the FRA:1JZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
90GF Score
Get the complete analysis for FRA:1JZ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JZ has been successfully added to your 
